Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prophase Labs Inc (NQ: PRPH )

0.7700 +0.0324 (+4.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prophase Labs Inc

< Previous 1 2 3 Next >
US Stocks Mixed; Fluor Earnings Miss Views
Via Benzinga
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Upstart Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt
IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders. 
Via Benzinga
ProPhase Labs's Earnings: A Preview
Via Benzinga
ProPhase Labs Earnings Preview
Via Benzinga
Analyst Expectations for ProPhase Labs's Future
Via Benzinga
Recap: ProPhase Labs Q1 Earnings
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
ProPhase Labs's Earnings: A Preview
Via Benzinga
S&P 500 Tops 6,000; Sezzle Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Tops 44,000; US Consumer Sentiment Increases In November
Via Benzinga
Topics Stocks
Exposures US Equities
Why ProPhase Labs (PRPH) Stock Is Down 47% Today
ProPhase Labs shares are trading lower by 50% during Friday's session. The company announced a 4.17 million share offering at 72 cents per share, totaling $3 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
ProPhase Labs Earnings Preview
Via Benzinga
PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q2 2024
PRPH stock results show that ProPhase Labs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
PRPH Stock Earnings: ProPhase Labs Beats EPS, Misses Revenue for Q1 2024
PRPH stock results show that ProPhase Labs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023
PRPH stock results show that ProPhase Labs missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 15, 2024
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 99 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During the Friday's sesion, 157 stocks hit new 52-week lows. 
Via Benzinga
DSS, Inc.'s (NYSE American: DSS) Subsidiary Appoints New Chief Investment Officer To Aggressively Develop Mutual Fund Business For Eventual Spinoff
DSS Wealth, Inc. has appointed Daniel Lew as its new Chief Investment Officer (CIO) and Portfolio Manager. DSS Wealth is a mutual fund and a wholly-owned subsidiary of DSS, Inc. 
Via Benzinga
DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement
DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement 
Via News Direct
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement
By David Willey, Benzinga 
Via TheNewswire.com
DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement
DSS, Inc. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
Via InvestorPlace
Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?
Impact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and conditions and one of the key businesses in the DSS Inc. (NYSE American: DSS)... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.